BRPI0513303A - uso de l-carnitina para o tratamento de doenças cardiovasculares - Google Patents

uso de l-carnitina para o tratamento de doenças cardiovasculares

Info

Publication number
BRPI0513303A
BRPI0513303A BRPI0513303-3A BRPI0513303A BRPI0513303A BR PI0513303 A BRPI0513303 A BR PI0513303A BR PI0513303 A BRPI0513303 A BR PI0513303A BR PI0513303 A BRPI0513303 A BR PI0513303A
Authority
BR
Brazil
Prior art keywords
carnitine
infarction
treatment
grams
days
Prior art date
Application number
BRPI0513303-3A
Other languages
English (en)
Inventor
Aleardo Koverech
Original Assignee
Sigma Tau Ind Famaceutiche Riu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Famaceutiche Riu filed Critical Sigma Tau Ind Famaceutiche Riu
Publication of BRPI0513303A publication Critical patent/BRPI0513303A/pt
Publication of BRPI0513303A8 publication Critical patent/BRPI0513303A8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004Monosaccharides having only carbon, hydrogen and oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

USO DE L-CARNITINA PARA O TRATAMENTO DE DOENçAS CARDIOVASCULARES. A presente invenção refere-se ao uso de L-carnitina, ou um de seus sais farmaceuticamente aceitáveis, é descrito em combinação com glicose para a preparação de um medicamento útil para diminuir o número de mortes causadas por infarto do miocárdio agudo, para reduzir o número de dias gasto por pacientes de infarto em cuidados intensivos em hospital, e para reduzir o número de episódios de insuficiência cardíaca pós-infarto, em que a L-carnitina é administrada intravenosamente dentro apenas de algumas horas do início de sintomas de infarto do miocárdio agudo em uma dose inicial de 9 gramas ao dia em combinação com 1000 a 1500 mL de uma solução de glicose a 5% durante 5 dias, após o que o tratamento com L-carnitina é continuado em uma dose de 4 gramas ao dia administrados oralmente.
BRPI0513303A 2004-07-13 2005-06-21 Uso de l-carnitina para o tratamento de doenças cardiovasculares BRPI0513303A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000346A ITRM20040346A1 (it) 2004-07-13 2004-07-13 Uso della l-carnitina per il trattamento di patologie cardiovascolari.
PCT/EP2005/006657 WO2006005415A2 (en) 2004-07-13 2005-06-21 Use of l-carnitine and glucose for the treatment of cardiovascular diseases

Publications (2)

Publication Number Publication Date
BRPI0513303A true BRPI0513303A (pt) 2008-05-06
BRPI0513303A8 BRPI0513303A8 (pt) 2017-12-26

Family

ID=34971575

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513303A BRPI0513303A8 (pt) 2004-07-13 2005-06-21 Uso de l-carnitina para o tratamento de doenças cardiovasculares

Country Status (22)

Country Link
US (2) US7879908B2 (pt)
EP (1) EP1773314B1 (pt)
JP (1) JP5230195B2 (pt)
KR (1) KR101296479B1 (pt)
CN (2) CN102349923B (pt)
AT (1) ATE542529T1 (pt)
AU (1) AU2005262050B2 (pt)
BR (1) BRPI0513303A8 (pt)
CA (1) CA2569888C (pt)
CY (1) CY1112686T1 (pt)
DK (1) DK1773314T3 (pt)
ES (1) ES2380913T3 (pt)
HK (2) HK1113542A1 (pt)
HR (1) HRP20120178T1 (pt)
IT (1) ITRM20040346A1 (pt)
ME (1) ME01345B (pt)
MX (1) MXPA06014665A (pt)
PL (1) PL1773314T3 (pt)
PT (1) PT1773314E (pt)
RS (1) RS52253B (pt)
SI (1) SI1773314T1 (pt)
WO (1) WO2006005415A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086543A1 (es) * 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1120033B (it) * 1979-10-05 1986-03-19 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente-carnitina adatta per l'alimentazione parenterale
JPS6415220A (en) 1987-07-06 1989-01-19 Mitsubishi Electric Corp Tension control device for utilizing maximum torque and maximum electric current of winding motor
JPH06102624B2 (ja) * 1990-08-10 1994-12-14 アース製薬株式会社 非心臓由来の不整脈防止薬
IT1261695B (it) 1993-06-02 1996-05-29 Sigma Tau Ind Farmaceuti Impiego di l-carnitina e alcanoil l-carnitine nella conservazione del sangue per trasfusioni e soluzioni stabilizzatrici che le contengono.
US5998386A (en) * 1997-09-19 1999-12-07 Feldman; Arthur M. Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue
WO2000030637A1 (en) * 1998-11-26 2000-06-02 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of fumarate salt of l-carnitine or its alkanoyl derivatives in ischaemia
DK1220670T3 (da) * 1999-10-11 2006-12-18 Sigma Tau Ind Farmaceuti Anvendelse af L-carnitin og dets alkanoylderivater som osmotiske stoffer i oplösninger til medicinsk anvendelse
CA2480557C (en) * 2002-04-01 2013-02-19 Gary David Lopaschuk Cycloalkylcarboxyl derivatives that stimulate glucose utilization and methods of use
ITRM20030178A1 (it) 2003-04-17 2004-10-18 Sigma Tau Ind Farmaceuti Uso della l-carnitina per il trattamento di patologie cardiovascolari.

Also Published As

Publication number Publication date
PT1773314E (pt) 2012-03-29
JP2008517872A (ja) 2008-05-29
US20110086917A1 (en) 2011-04-14
JP5230195B2 (ja) 2013-07-10
ES2380913T3 (es) 2012-05-21
CA2569888C (en) 2013-08-13
US7879908B2 (en) 2011-02-01
CN101087602B (zh) 2011-09-14
US20070207970A1 (en) 2007-09-06
CA2569888A1 (en) 2006-01-19
SI1773314T1 (sl) 2012-04-30
AU2005262050A1 (en) 2006-01-19
HK1113542A1 (en) 2008-10-10
WO2006005415A2 (en) 2006-01-19
PL1773314T3 (pl) 2012-06-29
BRPI0513303A8 (pt) 2017-12-26
WO2006005415A3 (en) 2006-05-26
ATE542529T1 (de) 2012-02-15
US8394854B2 (en) 2013-03-12
HK1166003A1 (zh) 2012-10-19
AU2005262050B2 (en) 2011-02-24
ITRM20040346A1 (it) 2004-10-13
DK1773314T3 (da) 2012-05-07
ME01345B (me) 2012-10-31
CN102349923B (zh) 2016-04-27
RS52253B (en) 2012-10-31
CN101087602A (zh) 2007-12-12
HRP20120178T1 (hr) 2012-05-31
KR20070039541A (ko) 2007-04-12
CN102349923A (zh) 2012-02-15
CY1112686T1 (el) 2016-02-10
EP1773314B1 (en) 2012-01-25
MXPA06014665A (es) 2007-03-12
EP1773314A2 (en) 2007-04-18
KR101296479B1 (ko) 2013-08-13

Similar Documents

Publication Publication Date Title
Jaspan et al. Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function
AR040682A1 (es) Forma de dosificacion una vez al dia de pramipexol
JP7208139B2 (ja) 双極性障害の予防、軽減又は治療のためのカルバメート化合物の使用
BRPI0513303A (pt) uso de l-carnitina para o tratamento de doenças cardiovasculares
ES2247060T3 (es) Producto que comprende un inhibidor de la transduccion de las señales de las proteinas g heterotrimericas en asociacion con un agente antihipertensor para una utilizacion terapeutica en el tratamiento de la hipertension arterial.
CA2450915A1 (en) Use of levosimendan and beta-adrenergic receptor antagonist for the treatment of heart failure
BRPI0406552A (pt) Uso de l-carnitina para o tratamento de doenças cardiovasculares
JP4381685B2 (ja) 2型インスリン抵抗性真性糖尿病患者の治療のためのビオチンと組合せてのアセチルl−カルニチンの使用
JP2006045200A (ja) 間質性膀胱炎の治療薬
ROY et al. Milestones In Diabetes Research
Ayache et al. Methylphenidate in a patient with depression and respiratory insufficiency
Prabhu et al. Digital gangrene due to dopamine infusion-a case report
McDaniel Antidepressant activity of linezolid
Shankar et al. Hyperglycemia induced hemichoreoathetosis, an uncommon presenting symptom of diabetes mellitus
JP2008517872A5 (pt)
JP2022546134A (ja) 自閉症スペクトル障害の治療における使用のためのバフィデムスタット
Okonta Pharmacodynamic drug interaction study: effect of sertraline on the hypoglucemic action of glibenclamide in rats
Placebo-Controlled Original Research Efficacy and Safety of Adjunctive Armodafinil
József Simkó et al. Sinus node dysfunction due to psychotropic agents combination
UA70535A (en) Method for preventing paroxysms of atrial fibrillamethod for preventing paroxysms of atrial fibrillation in ischemic disease of heart in elderly tion in ischemic disease of heart in elderly

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: ALFASIGMA S.P.A. (IT)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL